Gilead and Novo Nordisk collaborate for NASH trialGilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) Share XGilead and Novo Nordisk collaborate for NASH trialhttps://pharmaphorum.com/news/gilead-and-novo-nordisk-collaborate-for-nash-trial/
Wave slips behind in Huntington’s disease antisense raceSlower-than-expected recruitment in trials of two of Wave Life Sciences’ experimental therapies of Huntington’s disease will delay results, Share XWave slips behind in Huntington’s disease antisense racehttps://pharmaphorum.com/news/wave-huntingtons-disease-antisense-race/
Syncona joins Gyroscope, Orbit to create eye gene therapy playerUK biotech Gyroscope Therapeutics is to merge with Orbit Biomedical of the US to create a specialist in Share XSyncona joins Gyroscope, Orbit to create eye gene therapy playerhttps://pharmaphorum.com/news/syncona-gyroscope-orbit-eye-gene-therapy/
Janssen announces first data centres for haematology networkJanssen has announced the first two data centres to join its HONEUR (Haematology Outcomes Network in Europe) collaborative Share XJanssen announces first data centres for haematology networkhttps://pharmaphorum.com/news/janssen-announces-first-data-centres-for-haematology-network/
Sandoz to commercialise opioid induced constipation tablet in EUAs it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi Share XSandoz to commercialise opioid induced constipation tablet in EUhttps://pharmaphorum.com/news/sandoz-to-commercialise-opioid-induced-constipation-tablet-in-eu/
FCB Health NY makes Kathleen Nanda executive creative directorKathleen Nanda has been promoted to executive creative director of FCB Health New York. She joined the communications Share XFCB Health NY makes Kathleen Nanda executive creative directorhttps://pharmaphorum.com/news/fcb-health-new-york-kathleen-nanda/
Trial sets up 2020 filing for Poxel’s novel diabetes drugFrench biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 Share XTrial sets up 2020 filing for Poxel’s novel diabetes drughttps://pharmaphorum.com/news/trial-sets-up-2020-filing-for-poxels-novel-diabetes-drug/
Indivior stung by fraud charges over US marketingShares in UK drugmaker Indivior have gone into freefall after it was charged by the US Department of Share XIndivior stung by fraud charges over US marketinghttps://pharmaphorum.com/news/indivior-stung-by-fraud-charges-over-us-marketing/
Drug middlemen point finger at pharma in US pricing debateThe so-called ‘middlemen’ in the US pharma supply chain have blamed big pharma for skyrocketing drug prices in Share XDrug middlemen point finger at pharma in US pricing debatehttps://pharmaphorum.com/news/drug-middlemen-point-finger-at-pharma-in-us-pricing-debate/
